Poltreg SA and its wholly owned Subsidiary, Immuthera, are pioneers in T-Regulatory cell therapy (Tregs). PolTREG is a fully integrated clinical stage company with extensive clinical experience with Tregs, a pipeline of advanced Treg and mRNA immunotherapies, and commercial stage cGMP cell manufacturing. Immuthera has recently launched in the US and will be bringing Treg cell therapies and other technologies licensed from PolTREG, into the US starting with Presymptomatic (Stage 1 & 2) T1D and Progressive MS.